Business
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass., May 07, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the first quarter ended March 31, 2026, and provided an update on recent company developments.
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/9445ccaa33cc9eea75440179ca87802c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aTM1PncyRX.x9HWvB6AdFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMA--/https://media.zenfs.com/en/business-wire.com/9445ccaa33cc9eea75440179ca87802c","width":480,"height":200},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZKlVtcVjIy9iEDVSIHx85g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI2Nw--/https://media.zenfs.com/en/business-wire.com/9445ccaa33cc9eea75440179ca87802c","width":480,"height":200}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date","length":207,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of Novo Nordisk), and a second U.S.-based facility","length":139,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"FDA has completed reinspection of Catalent Indiana; classification of facility expected within 90 days following reinspection, in accordance with FDA guidelines","length":160,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Second fill-finish facility on track to have commercial apitegromab supply in early Q3 2026","length":91,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30, 2026","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash, cash equivalents, and marketable securities of $480 million as of March 31, 2026; includes an additional $100 million in debt and $98 million in net cash proceeds from the Company’s at-the-market (ATM) program","length":215,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Management to host a conference call today at 8:00 a.m. ET","length":58,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1013,"olType":false},{"type":"text","con...